The natural history of metaplasia and dysplasia in Barrett esophagus is not well defined. Publication bias, the selective reporting of studies that have positive or extreme results, has exaggerated the risk of esophageal adenocarcinoma in this condition. Recent data suggest that patients with Barrett esophagus develop these tumors at the rate of 0.5% per year, a cancer incidence considerably lower than was appreciated just a few years ago. Indirect evidence suggests that aggressive treatment of gastroesophageal reflux might decrease the risk of carcinogenesis, but no therapy yet has been proved to decrease the incidence of cancer in Barrett esophagus. Dysplasia in the metaplastic epithelium clearly is a worrisome finding, but the progression from dysplasia to cancer may take years and may not be inevitable.
I n most individuals with reflux esophagitis, the injured esophageal squamous epithelium heals through the regeneration of more squamous cells. In some individuals, for reasons that are not clear, reflux esophagitis heals through a metaplastic process in which columnar cells replace the damaged squamous ones. The resulting condition is called Barrett esophagus. 1 The abnormal epithelium that characterizes Barrett esophagus is an incomplete form of intestinal metaplasia, composed of columnar cells that can have gastric, small intestinal, and colonic features. This "specialized intestinal metaplasia" is predisposed to genetic abnormalities that eventuate in esophageal adenocarcinoma, 2 a tumor whose frequency has increased profoundly over the past few decades in Western countries. 3 In addition to gastroesophageal reflux disease (GERD), risk factors for Barrett esophagus and adenocarcinoma include male sex, white ethnicity, advanced age, and obesity. 4, 5 Barrett esophagus and its associated adenocarcinoma have long been known to have a strong predilection for whites. 5 One recent study suggests that all of the esophageal complications of GERD (Barrett esophagus, peptic esophageal ulceration, and peptic esophageal stricture) affect whites predominantly and are uncommon in blacks and Asians.
6 Among 2,477 consecutive patients seen in the general endoscopy unit of a Boston hospital, one or more GERD complications were seen in 267 (12.3%) of 2,174 white patients but in only 7 (2.8%) of 249 black patients and 1 (1.8%) of 54 Asian patients; 194 of the 201 patients found to have Barrett esophagus were white, as were 61 of the 62 patients with peptic esophageal ulcerations and all of the 50 patients with peptic esophageal strictures. These observations suggest that the development of GERD and the response to reflux esophagitis are strongly influenced by genetic factors.
RISK OF CANCER IN BARRETT ESOPHAGUS
Published estimates on the annual risk of cancer in patients with Barrett esophagus have ranged from 0.2% to 2.9%. 7 Some researchers have pooled data from studies on this issue to derive a composite estimate of cancer risk in Barrett esophagus of ≈1% per year. 8 However, the studies on which that estimate was based involved primarily patients referred to tertiary care centers whose cancer risk may exceed that for patients treated in primary care practices. Furthermore, a recent report by Shaheen et al. 7 suggested that the cancer risk in Barrett esophagus has been overestimated because of publication bias, the selective reporting of studies that have positive or extreme results. The investigators started with the premise that cancer risk estimates derived from small studies should be less accurate than those from large studies because of sampling error. Without publication bias, a group of small studies should describe a relatively wide range of risk estimates, and those estimates should be symmetrically distributed around the midpoint value. If there is publication bias, however, reports of small studies that find low risks either will not be submitted to journals at all or will be rejected by editors who deem the reports uninteresting. In this situation, the preponderance of small studies published will describe high risks. Shaheen et al. 7 found strong evidence of such publication bias among 24 published studies on cancer risk in Barrett esophagus. They estimated that patients with Barrett esophagus develop esophageal cancer at the rate of 0.5% per year, an incidence similar to that reported in several of the largest modern studies on this issue. [8] [9] [10] Cancers in Barrett esophagus develop through the accumulation of genetic mutations that endow the cells with growth advantages. Whereas mutations are chance events to some extent, logic suggests that the risk of cancer in Barrett esophagus should be higher in patients with longer segments of metaplastic epithelium. Such patients would have more cells at risk for DNA damage and therefore should be more likely to acquire the critical mutations that cause malignancy. Although considerable circumstantial evidence supports this hypothesis, there is yet no proof that the risk of cancer varies with the extent of the esophageal metaplastic lining. In one recent report describing 235 patients with Barrett esophagus, no significant differences in cancer risk were found among groups with varying lengths of esophageal metaplasia. 11 Nevertheless, there was a trend suggesting an association between extent of metaplasia and cancer risk. Pending further studies that clarify this issue, patients with short-segment Barrett esophagus presently are managed as if they have the same cancer risk as their counterparts with long-segment Barrett esophagus.
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EFFECT OF TREATMENT ON CANCER RISK
Although aggressive antireflux therapy has been proposed as a means to prevent cancer in patients with Barrett esophagus, there is no proof that such therapy indeed affects the cancer risk. It is not clear whether GERD predisposes to malignancy because GERD causes Barrett esophagus, because GERD promotes carcinogenesis in established Barrett esophagus, or both. If the primary carcinogenetic role of GERD is in causing the initial metaplasia, then subsequent antireflux therapy might have little effect on tumor development.
Several observations have suggested that aggressive GERD treatment might prevent cancer in Barrett esophagus. For example, esophageal acid perfusion has been shown to activate the mitogen-activated protein kinase pathways that increase proliferation and decrease apoptosis in Barrett esophagus. 12 Biopsy specimens of Barrett esophagus maintained in organ culture have exhibited hyperproliferation when exposed to acid for 1 hour. 13, 14 In a study of patients who had esophageal biopsy specimens taken at baseline and after 6 months of treatment with a proton pump inhibitor (PPI), specimens from those with normal esophageal acid exposure had decreased expression of the proliferation marker PCNA, whereas no such decrease was observed in those with persistently abnormal acid reflux. 15 Another study found no significant change in the proliferative activity of Barrett esophagus in patients treated with a PPI for 2 years, whereas that activity increased significantly in patients treated with a histamine H2-receptor antagonist (an agent substantially less effective than PPIs for decreasing gastric acid secretion). 16 Chronic PPI therapy also has been shown to cause partial regression of specialized intestinal metaplasia. 17 Nevertheless, proof that antisecretory therapy decreases cancer risk in Barrett esophagus will require welldesigned clinical trials. Presently, prescription of antireflux therapy beyond that necessary to effect healing of the symptoms and signs of GERD has not been endorsed specifically by the medical societies that have addressed this issue. 1, 18 Surgical enthusiasts have admonished physicians to beware of PPI effects that, in theory, might promote carcinogenesis in Barrett esophagus. 19 For example, potent acid suppression can result in gastric colonization with bacteria that convert dietary nitrates to carcinogenic nitrosamines 20 and that deconjugate bile acids. 21 Deconjugated bile acids in gastric juice might be toxic to the esophageal mucosa at the neutral pH levels induced by PPI therapy. [21] [22] [23] Indeed, some uncontrolled studies found fewer cases of dysplasia and cancer in patients with Barrett esophagus who had fundoplications than in those who had received medical antireflux therapy. 24 Two recent reports provide little support for the contention that fundoplication prevents esophageal cancer better than antisecretory therapy. 10, 25 One report described the results of long-term follow-up of 247 veteran patients with complicated GERD who had participated in a randomized trial of medical and surgical antireflux therapies. 10 There was no significant difference between the treatment groups in the rate of esophageal cancer development, and there was an unexplained (but significant) decrease in survival for the surgical patients due to excess deaths from heart disease. The other report described the results of a large, Swedish population-based cohort study in which patients with GERD were followed for up to 32 years. 25 The relative risk for developing esophageal adenocarcinoma (compared with the general population) in 35,274 men who received medical antireflux therapy was 6.3 (95% CI, 4.5-8.7), whereas the relative risk for 6,406 men treated with fundoplication was 14.1 (95% CI, 8.0-22.8). Despite the proposed theoretical advantages for antireflux surgery, these two powerful studies do not support the prescription of fundoplication as a means to prevent cancer deaths in Barrett esophagus.
Finally, it has been proposed that nonsteroidal antiinflammatory drugs, which inhibit cyclooxygenase, might have a chemopreventive role in Barrett esophagus. Epidemiological studies have suggested that the regular use of aspirin may protect against cancer of the esophagus. 26 Overexpression of cyclooxygenase-2 has been found in Barrett esophagus, 27 and inhibition of cyclooxygenase-2 has been shown to have antiproliferative and proapoptotic effects in Barrett-associated esophageal adenocarcinoma cell lines. 28 Despite these promising data, prospective clinical studies are needed before nonsteroidal antiinflammatory drugs can be recommended for chemoprevention in Barrett esophagus.
NATURAL HISTORY OF DYSPLASIA IN
BARRETT ESOPHAGUS Dysplasia is a histologic diagnosis suggesting that one or more clones of cells have acquired genetic damage rendering them neoplastic and predisposed to malignancy. 29 Pa-thologists categorize dysplasia as low or high grade depending on the extent of cytologic and architectural changes. Although it is widely assumed that cancers in Barrett esophagus evolve through an orderly sequence of events in which the metaplastic epithelium first exhibits changes of low-grade dysplasia, followed by high-grade dysplasia, and ultimately cancer, in fact this sequence has been documented infrequently. For some patients found to have dysplasia, subsequent endoscopies may reveal no dysplastic epithelium. [30] [31] [32] In this situation, it is not clear whether the dysplasia was missed because of biopsy sampling error or the dysplasia regressed. In addition, adenocarcinomas have been found in patients whose earlier biopsy specimens revealed only low-grade or no dysplasia. 9, 32, 33 In those cases, it is not clear whether progressive dysplastic changes were missed because of biopsy sampling error, because of rapid progression from dysplasia to cancer between endoscopies, or because cancer developed with no intervening dysplastic changes.
Surprisingly few reports describe the natural history of high-grade dysplasia in Barrett esophagus, and three recent studies on this issue have provided disparate results. 31, 32, 34 These studies included only patients with high-grade dysplasia who had no tumor detected by extensive biopsy sampling. Reid et al. 31 found a 59% 5-year cumulative esophageal cancer incidence among 76 such patients. At the Mayo Clinic, Buttar et al. 34 followed 100 patients with highgrade dysplasia, 32 of whom were found to have adenocarcinoma during a follow-up period of up to 8 years. In this series, the extent of high-grade dysplasia in the initial biopsy specimens correlated with the cancer risk. The cumulative cancer incidence at 3 years was 14% among 33 patients with focal high-grade dysplasia compared with 56% among 67 patients with diffuse high-grade dysplasia. Schnell et al. 32 observed a much lower incidence of esophageal cancer among their 75 veteran patients with highgrade dysplasia. Only 12 (16%) of their patients developed adenocarcinoma during a mean follow-up period of 7.3 years. The reason for the disparities among these reports is not clear, but the latter study has been criticized for lacking external confirmation for the diagnosis of high-grade dysplasia. 29 There are even fewer meaningful published data on the natural history of low-grade dysplasia in Barrett esophagus. Weston et al. 35 followed 48 patients with low-grade dysplasia for a mean duration of 41 months and found that five patients (10%) had progression to high-grade dysplasia or adenocarcinoma. The Seattle group found a 12% cumulative incidence of adenocarcinoma at 5 years among 43 patients who had low-grade dysplasia during baseline endoscopy. 31 Skacel et al. 33 at the Cleveland Clinic followed 25 patients with low-grade dysplasia for a mean duration of 26 months, during which seven patients (28%) had progression to high-grade dysplasia or adenocarcinoma. In this series, agreement among pathologists on the diagnosis of low-grade dysplasia was associated with neoplastic progression. Seven (41%) of the 17 patients for whom at least two of the three study pathologists agreed on the diagnosis had progression, whereas progression was seen in four (80%) of the five patients for whom there was unanimous agreement among the study pathologists.
There are substantial risks associated with invasive therapies like esophagectomy and endoscopic ablation for high-grade dysplasia in Barrett esophagus. Noting these risks and the uncertainties regarding the natural history of the condition, some authorities have recommended that patients with high-grade dysplasia should have intensive endoscopic surveillance (i.e., endoscopic examinations every 3 to 6 months), withholding invasive therapies until biopsy specimens show adenocarcinoma. 31, 36 However, few published data directly support the safety and efficacy of intensive surveillance for high-grade dysplasia. In the Hines VA experience with 12 patients who developed adenocarcinoma during surveillance for high-grade dysplasia, the cancers were potentially curable at the time of detection in all but one patient (8%). 32 In the Seattle series of 32 patients with high-grade dysplasia who were found to develop adenocarcinoma while enrolled in a program of intensive endoscopic surveillance, one patient (3%) had incurable disease (metastases) when the cancer was first detected by surveillance endoscopy. 37 Weston et al. 38 followed 15 veteran patients with unifocal high-grade dysplasia, performing intensive surveillance for a mean duration of 36.8 months during which four patients developed adenocarcinoma. One (25%) of the four patients had metastatic disease, and the investigators concluded that an observational approach to the management of high-grade dysplasia should be discouraged.
CONCLUSION
There remains much to be learned about the natural history of metaplasia and dysplasia in Barrett esophagus. For most patients with this condition, cancers appear to develop at the rate of 0.5% per year, an incidence substantially lower than was appreciated just a few years ago. No therapy yet has been proved to decrease the incidence of cancer in Barrett esophagus. Dysplasia in the metaplastic epithelium clearly is a worrisome finding, but the progression from dysplasia to cancer may take years and may not be inevitable. Presently, few data document the safety of an observational approach to the management of high-grade dysplasia.
